March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message Search About Us Company Management Board of Directors Scientific Advisory Board Technology MVA-VLP Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators Investors Corporate Profile News Events SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's News & Media Contact Contact Us Careers
January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message
January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter × About GeoVax Company Management Board of Directors Scientific Advisory Board Our Technology Technology Overview Publications Investors Corporate Profile News SEC Filings GeoVax Stock Information Corporate Governance Analyst Coverage Investor FAQ's Product Pipeline Pipeline Summary Immuno-Oncology Infectious Diseases Collaborators SUBSCRIBE FOR UPDATES FROM GEOVAXRegister to receive email alerts for GeoVax press releases SUBMIT Message
January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter ×
January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter ×
January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter ×
